Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-01-27 (bloomberglaw.com)
This Week in Chancery Court: Biogen, T-Mobile, Repsol SA
Biogen Inc. is fending off a lawsuit in the Delaware Chancery Court over its recent offer to buy out Sage Therapeutics, its collaborator on a postpartum depression drug.
Read more
2025-01-07 (bankerandtradesman.com)
Court Rules Biogen Not to Blame for Subtenants’ Woes -
A Suffolk Superior Court judge dismissed a biomanufacturing company’s lawsuit that claimed disruption caused by a Kendall Square development caused it to lose virtually all of its long-term contracts.
Read more
2024-12-31 (healio.com)
Top neurology stories of 2024: The end of Aduhelm, misconduct in the NIH and more
Healio Neurology looks back at the most-viewed stories during the past year. Highlights include Biogen’s discontinuation of Aduhelm and a former NIH neuroscience director found guilty of research misconduct.Read these and more below:
Read more
2024-08-06 (cannabislaw.report)
Arkansas AG’ office files letter, apprising the court about recent district court rulings rejecting preemption challenges to state hemp laws that are stricter than federal law.
Posted to Linked in by Neil M. Willner- Co-chair, Cannabis Group at Royer Cooper Cohen Braun He writes In the BioGen v. Sarah Huckabee Sanders hashtag# hemp litigation( now on appeal in the 8th Circuit), the Arkansas AG' office filed a letter, apprising the court about recent district court rulings
Read more
2024-06-11 (medwatch.dk)
Biogen provides a two-digit million guarantee in the Danish copycat case
According to the court, the pharmaceutical manufacturer has provided the necessary million guarantees for a ban on Sandoz to come into force. Amgros has taken note of the course of the case.
Read more
2023-10-23 (reut.rs)
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche's blockbuster rheumatoid arthritis drug Actemra, according to a filing on Monday in Massachusetts federal court.
Read more
2023-10-17 (pionline.com)
Companies move to settle ERISA lawsuits in third quarter
During the third quarter of 2023, 58 ERISA-related lawsuits were filed and/or updated. Each event represents the involved parties either reaching a settlement or filing an appeal, or a court decision was made.
Read more
2023-03-29 (breakingnews.ie)
High Court wrongly found public interest in cheaper drugs overrode patent holder rights | BreakingNews.ie
A judge at the Court of Appeal said the High Court erred in principle in considering that patent holder, Biogen, had a “monopoly to which it was not entitled”
Read more
2023-03-29 (irishtimes.com)
High Court wrongly concluded public interest in cheaper drugs overrode patent holder rights, appeal court rules
There was ‘nothing unlawful’ in Biogen’s application for and exploitation of a parent patent
Read more
2023-03-16 (globenewswire.com)
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Court of Justice of the European Union decided...
Read more
2022-07-12 (bloomberglaw.com)
Biogen’s High Court Patent Case Bid Backed by Science Advocates
Biogen Inc. won the support of a science and legal advocacy group in its bid for US Supreme Court review of a Federal Circuit ruling that will allow Mylan Pharmaceuticals Inc. and other generic drugmakers to sell copycats of the multiple sclerosis
Read more
2022-07-06 (bloomberglaw.com)
Biogen Whistleblower Wins Favorable Pretrial Ruling on Kickbacks
A False Claims Act whistleblower accusing Biogen Inc. of submitting payment claims to the government tainted by kickbacks to physicians convinced a federal district court that violations of the Anti-Kickback Statute are material to federal healthcare
Read more